GlassScriptPhysician profile
Ali M Nasser
NPI 1477513158
$2,797.09
in general payments reported to CMS, 2019-2025
27 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $33.94 · 2021: $244 · 2022: $369 · 2023: $311 · 2024: $380 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $377.37 | 2019-2021 | |
| Amgen INC. | $278.52 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.35 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $231.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $221.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $187.31 | 2019-2024 | Verquvo |
| Lilly USA, LLC | $167.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Axsome Therapeutics, INC. | $124.74 | 2025 | Symbravo |
| Astellas Pharma US INC | $115.38 | 2024 | Xtandi |
| Abbvie INC. | $105.43 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $90.00 | 2019 | |
| Exact Sciences Corporation | $69.36 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $64.69 | 2021-2022 | |
| Optos, INC. | $58.90 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48.10 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $47.42 | 2019-2025 | Trelegy Ellipta |
| Shield Therapeutics INC | $40.77 | 2022-2023 | Accrufer |
| Abbott Laboratories | $25.79 | 2022 | |
| Inspire Medical Systems, INC. | $24.46 | 2023 | Inspire |
| Tactile Systems Technology INC | $24.38 | 2024 | Entre Plus, Flexitouch Plus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.20 | 2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $15.73 | 2023 | |
| Recor Medical INC | $15.05 | 2025 | Paradise Ultrasound Renal Denervation System |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.